来源：金融界 经营范围含第二类医疗器械销售；第二类医疗设备租赁；第一类医疗设备租赁；医护人员防护用品生产 （Ⅰ类医疗器械）；第一类医疗器械生产；技术服务、技术开发、技术咨询、技术交流、技术转让、技 术推广；货物进出口；医护人员防护用品批发；医用口罩批发；软件开发；软件销售；软件外包服务； 人工智能应用软件开发；人工智能基础软件开发；人工智能理论与算法软件开发；计算机软硬件及辅助 设备批发；会议及展览服务；机械设备租赁；机械设备销售；机械设备研发；普通机械设备安装服务； 电子产品销售；智能机器人销售；智能机器人的研发；光学仪器销售；机械零件、零部件销售；信息系 统集成服务；数据处理和存储支持服务；承接档案服务外包；远程健康管理服务；健康咨询服务（不含 诊疗服务）；人体干细胞技术开发和应用；医学研究和试验发展。（除依法须经批准的项目外，凭营业 执照依法自主开展经营活动） 企业名称深圳德尚普博医疗科技有限公司法定代表人杨璐瑶注册资本200万人民币国标行业制造业>医 药制造业>化学药品制剂制造地址深圳市宝安区福海街道新田社区新田大道71-3号501企业类型有限责任 公司营业期限2025-5-16至无固定期限登记机关 ...

Core Viewpoint - The number of "A+H" companies is significantly increasing in 2025, driven by favorable policies supporting domestic companies to list in Hong Kong, with expectations that the total will exceed the number from 2022 [1][2][3] Group 1: A+H Company Listings - In 2025, 22 A-share companies have submitted applications to list on the Hong Kong Stock Exchange, with 11 of these submissions occurring in April alone [2] - As of now, 25 A-share companies have applied to list in Hong Kong, with 22 being first-time applicants this year [2] - Notable companies like Ningde Times and Heng Rui Pharmaceutical have passed the Hong Kong Stock Exchange's hearing and are expected to list soon [2][3] Group 2: Financing and Internationalization - Many A-share companies aim to leverage Hong Kong's financing capabilities to accelerate their internationalization process [3][5] - Companies like Midea Group and SF Holding have outlined their fundraising purposes to enhance global operations and logistics networks [3][5] Group 3: Regulatory Support - A series of supportive policies initiated in April 2024 has facilitated the surge in companies seeking to list in Hong Kong [6][7] - The China Securities Regulatory Commission has streamlined the approval process for companies looking to list abroad, reducing the time and requirements for applications [7][8] Group 4: Market Performance Post-Listing - Companies that have listed in Hong Kong have shown significant growth in overseas business and overall revenue, with Midea's overseas e-commerce sales increasing over 50% year-on-year [4][10] - The performance of A+H companies post-listing indicates a narrowing of the price difference between A-shares and H-shares, reflecting improved market conditions [10][11] Group 5: Future Outlook - Deloitte forecasts that the total amount raised from IPOs in Hong Kong could reach between 130 billion to 150 billion HKD in 2025, potentially placing it back among the top three global markets for new stock offerings [1][9] - The trend of A-share companies listing in Hong Kong is expected to continue, with an anticipated wave of IPOs in the second half of 2025 [2][9]

Core Viewpoint - The rapid approval and construction processes in Huangqiao are significantly enhancing project efficiency, exemplified by the swift progress of Suzhou Dingdi Electric's project, which showcases the "Huangqiao speed" in economic stability through project construction [1][2]. Group 1: Project Efficiency - Suzhou Dingdi Electric's project received all necessary approvals within one month, achieving "land acquisition and immediate commencement" [1]. - The project, focused on AI and new energy power equipment, aims for an annual production capacity of nearly 60,000 units of advanced electrical equipment [1]. - The approval process was notably expedited, with the engineering planning permit and construction permit granted within 9 and 15 days, respectively [1]. Group 2: Government Initiatives - Huangqiao implemented a work mechanism emphasizing "node-driven, element pre-positioning, and bottleneck elimination" to streamline project approvals [2]. - A project service team was established to manage the entire lifecycle from project initiation to completion, promoting early commencement and production [2]. - The approach aims to create a positive development pattern with a focus on project transformation, commencement, progress, and output [2].

Group 1: Event Overview - The 2025 Investor Online Reception Day and Performance Briefing for listed companies in Heilongjiang was held on May 14, with over 120 executives from 36 companies participating [3][4] - The event focused on corporate governance, operational status, financial reports, development strategies, risk management, and sustainable development, addressing investor concerns [3][4] Group 2: Key Topics Discussed - High-frequency topics included "innovation development," "market value management," "shareholder returns," "profit growth points," and "future planning" during the nearly two-hour live interaction [3] - A total of 1,220 questions were raised by investors, with 928 questions answered by company representatives, resulting in an overall response rate of 76% [3] Group 3: Technological Innovation and Industry Upgrades - Companies like Zhongzhi Co. are focusing on technological upgrades in response to the rapid development of emerging industries such as artificial intelligence and low-altitude economy [4] - Zhongzhi Co. has integrated its helicopter business assets through restructuring, enhancing its gross margin and return on equity (ROE) [4] Group 4: Business Strategies and Market Positioning - Boshi Co. is investing heavily in smart factory solutions, integrating AI technologies with industrial internet communications to enhance production safety and efficiency [5] - Companies like Guolian Aviation and Guangzhi Technology are committed to increasing R&D investment and technological innovation to achieve high-quality development amid competitive pressures [5] Group 5: Value Creation and Market Confidence - Beidahuang plans to distribute a total cash dividend of 978 million yuan, with a payout ratio of 89.93%, an increase of 16.4 percentage points from the previous year [6] - Dong'an Power aims to sell 600,000 complete machines in 2025, a growth of over 20% compared to the previous year, to improve profitability through increased sales volume [6] Group 6: Strategic Development Focus - Haya Co. is focusing on major disease areas such as cardiovascular, digestive, respiratory, and oncology, aiming to develop competitive products in the elderly and children's medication sectors [9] - Huadian Energy achieved a net profit of 166 million yuan in 2024, marking a turnaround, and plans to optimize its energy structure in response to industry changes [9][10]

Group 1 - Multiple regions in China are implementing supportive policies for the elderly care industry, including Guangzhou and Shaanxi, aiming to enhance the financial services for elderly care and establish a robust support system by 2035 [1][2] - Shenzhen has released implementation opinions focusing on pension finance, elderly service finance, and elderly industry finance, with 17 specific measures to create a high-quality elderly care model [2] - The aging population in China is projected to exceed 310 million by the end of 2024, creating significant opportunities for the elderly care industry, with a market size expected to reach approximately 106 trillion yuan by 2050 [2] Group 2 - As of May 14, 2023, over 40 stocks related to the elderly care industry in A-shares have seen an average price increase of 2.21% this year, with notable performers like Miaokelan and Haoyue Nursing rising over 40% [3] - Approximately half of the elderly care concept stocks have received increased leverage funding, with significant net purchases exceeding 100 million yuan for companies like Aier Eye Hospital and Heng Rui Medicine [3] - In Q1 2024, 17 elderly care concept stocks reported net profits exceeding 100 million yuan, with China Life Insurance leading at 28.802 billion yuan, reflecting a substantial year-on-year growth of 39.5% [3] Group 3 - Zhejiang Medicine and New Harmony achieved remarkable net profit growth of 273.08% and 116.18% respectively in Q1, indicating strong performance in the elderly care sector [4] - Among the high-performing stocks with net profits over 100 million yuan, 12 received ratings from at least five institutions, with projected profit growth for 2025, including predictions of 88.64% for Covestro and 18.62% for Hualan Biological [4]

证券代码： 002900 证券简称：哈三联 哈尔滨三联药业股份有限公司 投资者关系活动记录表 编号：2025-001 | 投资者关系活 | □特定对象调研 □ 分析师会议 | | □ 现场参观 | | --- | --- | --- | --- | | 动类别 | □ 媒体采访 | √ 业绩说明会 | □ 其他 | | | □ 新闻发布会 | □ 路演活动 | | | 参与单位名称 | 关于参加黑龙江辖区上市公司 年投资者网上集体接待日活动暨业 | 2025 | | | 及人员姓名 | 绩说明会，投资者网上提问。 | | | | 时间 | 2025 年 5 月 14 日（周三）下午 14:00~16:30 | | | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 公司接待人员 | 1、董事、副总裁兼董事会秘书梁延飞先生 | | | | 姓名 | 2、财务总监赵志成先生 | | | | | 1、公司医美产业发展如何？有没有特色优势产品？ | | | | | 尊敬的投资者您好：公司大健康板块目前包括化妆品、医用敷料、 | | | | | "好好"系列纳米乳化饮 ...

金融界消息 截至2025年5月14日收盘，*ST苏吴（600200）报收于2.51元，下跌4.92%，换手率3.1%，成 交量22.04万手，成交金额5568.48万元。 来源：金融界 资金流向方面，今日主力资金净流出1557.82万元，占比成交额27.98%。其中，超大单净流出925.25万 元、占成交额16.62%，大单净流出632.57万元、占成交额11.36%，中单净流出流入0.31万元、占成交额 0.01%，小单净流入1557.51万元、占成交额27.97%。 天眼查商业履历信息显示，江苏吴中医药发展股份有限公司，成立于1994年，位于苏州市，是一家以从 事医药制造业为主的企业。企业注册资本71215.1832万人民币，实缴资本12279.5762万人民币。公司法 定代表人为钱群山。 通过天眼查大数据分析，江苏吴中医药发展股份有限公司共对外投资了13家企业，参与招投标项目5 次，知识产权方面有商标信息46条，专利信息2条，此外企业还拥有行政许可9个。 *ST苏吴最新一期业绩显示，截至2025一季报，公司营业总收入3.17亿元、同比减少25.44%，归属净利 润7031.79万元，同比减少1489.9 ...

Core Points - The company held its 2024 Annual General Meeting to discuss various proposals and reports, including financial performance and governance matters [1][5][6] Group 1: Financial Performance - In 2024, the company achieved a revenue of 602.62 million yuan, an increase of 0.42% compared to the previous year [24] - The net profit attributable to shareholders was -190.67 million yuan, a decrease of 4.33 million yuan from the previous year [7][22] - The company proposed not to distribute profits for 2024 due to the negative net profit, maintaining a focus on sustainable operations [22][26] Group 2: Governance and Reporting - The board of directors and the supervisory board presented their respective work reports, emphasizing compliance with legal and regulatory requirements [7][16] - The company plans to enhance its governance structure and internal control systems to ensure effective decision-making and operational efficiency [10][19] Group 3: Asset Management - The company proposed to recognize an asset impairment provision totaling 37.26 million yuan for various assets, including accounts receivable and inventory [29][30] - The company reported a significant reduction in various liabilities, including a 72.77% decrease in other current liabilities [27][28] Group 4: Future Financing - The company intends to apply for a comprehensive financing credit limit of up to 1 billion yuan from banks and financial institutions to support business development [30][31] - The company currently has an external guarantee balance of 312.61 million yuan, which exceeds its audited net assets [31]

Group 1 - The core viewpoint highlights the rapid development of the consumer goods industry in Liaoning, with local brands gaining national recognition and expanding their market presence [1][2] - The small North River town has successfully transformed local cultural symbols into wearable creative products, showcasing the potential of the region's textile industry [1] - Liaoning's consumer goods industry is diversifying, with notable achievements in various sectors such as swimwear, fur clothing, and socks, contributing to the province's economic growth [1][2] Group 2 - Liaoning has a strong foundation for developing consumer goods, with significant production capabilities in various categories, including silk, swimwear, and cashmere garments [2][3] - The province's industrial parks are becoming hubs for biomedicine, medical imaging equipment, and food industries, indicating a strategic focus on high-tech and high-value sectors [2] - There is a recognized gap between Liaoning's consumer goods industry and more advanced regions, prompting initiatives to enhance value addition, brand influence, and industrial ecology [3] Group 3 - The province aims to accelerate the high-end, intelligent, green, and integrated development of the consumer goods industry, focusing on traditional sectors while attracting advanced projects [3] - Liaoning plans to extend resource-based industrial chains and develop new consumer goods sectors, including health foods and biopharmaceuticals, to create new economic growth points [3] - Emphasis is placed on brand creativity and design to establish internationally recognized brands that reflect Liaoning's cultural elements [3]

[Table_subIndustry] 细分行业评级 医药制造业 增持 医药服务业 增持 本报告导读： 持续推荐创新药等投资主线 [Table_Industry] 医药 ——国泰海通医药 2025 年 5 月第一周周报 [Table_Invest] 评级： 增持 制药龙头恒瑞医药港股发行已通过港交所聆讯，有望持续催化创新药行情，持续推 进创新药等投资主线。 投资要点： 请务必阅读正文之后的免责条款部分 股 票 研 究 行 业 跟 踪 报 告 证 券 研 究 报 告 股票研究 /Table_Date] 2025.05.11 请务必阅读正文之后的免责条款部分 2 of 8 [table_Authors] 余文心分析师 郑琴分析师 谈嘉程分析师 02138676666 02138676666 02138676666 登记编号 S0880525040111 S0880525040108 S0880523070004 2025-05-12 [Table_Summary] 持续推荐创新药等投资主线。持续推荐景气度向上的创新药，维持 恒瑞医药、华东医药、翰森制药、贝达药业、信立泰、科伦药业、 百利天恒、荣昌生物、科伦博泰生 ...